

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

INITIATIVE FOR MEDICINES, ACCESS & KNOWLEDGE (I-MAK), INC.  
Petitioner

v.

GILEAD PHARMASSET LLC  
Patent Owner

---

Case No. IPR2018-00122  
U.S. Patent No. 8,334,270

---

**PETITION FOR *INTER PARTES* REVIEW**

## TABLE OF CONTENTS

I.	INTRODUCTION .....	1
II.	MANDATORY NOTICES .....	2
	A. Real Parties-in-Interest (37 C.F.R. § 42.8(b)(1)) .....	2
	B. Related Matters (37 C.F.R. § 42.8(b)(2)) .....	2
	C. Lead and Back-Up Counsel (37 C.F.R. § 42.8(b)(3)) .....	2
	D. Service Information (37 C.F.R. § 42.8(b)(4)) .....	2
III.	REQUIREMENTS FOR REVIEW .....	3
	A. Grounds For Standing .....	3
	B. Identification of Challenge .....	3
IV.	OVERVIEW OF THE '270 PATENT .....	4
V.	FILE HISTORY OF THE '270 PATENT .....	5
VI.	PERSON OF ORDINARY SKILL IN THE ART .....	5
VII.	CLAIM CONSTRUCTION .....	6
VIII.	BACKGROUND KNOWLEDGE IN THE ART .....	6
	A. The Use of Nucleoside Analogs As Antiviral Agents And Their Mechanism of Action Were Known .....	7
	B. Anti-Viral Nucleosides Must Be Converted Into Their Triphosphates To Be Active, Monophosphorylation Was The Rate-Limiting Step In Such Conversion, and 5'-Phosphate Prodrugs Enabled Nucleosides To Overcome This Limitation .....	12
	C. The Means Were Available to Determine Which Nucleosides Were Kinase Dependent .....	17

D.	Narrowing The Selection Of Options For The Phosphoramidate Prodrug .....	18
E.	Phosphoramidates Improved Nucleosides .....	18
F.	The ‘270 Patent Acknowledges This Common Knowledge .....	19
IX.	SCOPE AND CONTENT OF THE PRIOR ART .....	21
A.	Clark ‘147 .....	22
B.	Clark 2005 .....	23
C.	Perrone .....	25
D.	McGuigan ‘327 .....	26
X.	CLAIMS 1, 2, 10-18 AND 20-25 ARE UNPATENTABLE .....	27
A.	Ground 1: Claims 1, 2, 10-18 and 20-25 Were Obvious Over Clark ‘147, Clark 2005 and Perrone .....	28
1.	Claims 1, 2, 16-18 (compound) .....	28
2.	Claims 10-12 and 20-22 (compositions comprising compound) .....	43
3.	Claims 13-15 and 23-25 (methods of treating viral infections) .....	44
B.	Ground 2: Claims 1, 2, 10-18, 20-25 Were Obvious Over Clark ‘147, Clark 2005 and McGuigan ‘327 .....	45
1.	Claims 1, 2, 16-18 (compound) .....	45
2.	Claims 10-12 and 20-22 (compositions comprising compound) .....	57
3.	Claims 13-15 and 23-25 (methods of treating viral infections) .....	57
XI.	CONCLUSION .....	58
XII.	APPENDIX – LIST OF EXHIBITS .....	60
XIII.	CERTIFICATE OF COMPLIANCE .....	61

XIV. CERTIFICATE OF SERVICE.....62

## I. INTRODUCTION

Initiative for Medicines, Access & Knowledge (I-MAK), Inc. (“Petitioner”) requests *inter partes* review (“IPR”) of claims 1, 2, 10-18 and 20-25 of United States Patent No. 8,334,270 to Sofia et al. (“the ‘270 patent”; EX1001) under the provisions of 35 U.S.C. § 311, § 6 of the Leahy-Smith America Invents Act (“AIA”), and 37 C.F.R. § 42.100 et seq. The ‘270 patent issued on December 18, 2012, and is currently assigned to Gilead Pharmasset LLC (“Patent Owner”). This petition demonstrates that claims 1, 2, 10-18 and 20-25 of the ‘270 patent are unpatentable.

The ‘270 patent claims pharmaceutical compounds, compositions and methods that were obvious in light of the prior art. Specifically, the ‘270 claims a specific prodrug form of a specific nucleoside compound, but the prodrug technique used by Patent Owner was entirely conventional and the nucleoside compound to which Patent Owner applied the prodrug technique had been previously disclosed (and patented) by Patent Owner years before. Taking a known prodrug approach and applying it to a known nucleoside is not an invention. It’s obvious.

Thus, claims 1, 2, 10-18 and 20-25 of the ‘270 patent are unpatentable and should be cancelled.

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.